相关实验视频

Updated: Jul 28, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

在胰腺癌中准KRAS:新兴的治疗策略

Sajid Khan¹, Vivekananda Budamagunta², Daohong Zhou¹

¹Department of Biochemistry & Structural Biology, Long School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States; Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, United States.

Advances in cancer research

|June 2, 2023

概括

在胰腺癌中准KRAS突变是有前途的. 将KRAS抑制剂与其他疗法 (如BCL-XL降解剂) 结合起来,可以克服耐药性并增强细胞亡,从而获得更好的治疗结果.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症遗传学癌症遗传学

背景情况:

KRAS是胰腺癌中最常发生突变的瘤基因,驱动瘤生长和生存.
KRAS突变导致构成性通路的激活,促进增殖和抑制亡.
胰腺癌主要含有KRAS突变,如G12D和G12V,与当前抑制剂所针对的G12C突变不同.

研究的目的:

审查KRAS生物化学,信号和胰腺癌中的突变.
讨论新兴的针对KRAS的治疗方法和组合策略.
突出KRAS向胰腺癌治疗的挑战和未来方向.

主要方法:

对KRAS生物化学和信号通路的审查.
分析新兴的针对KRAS的治疗方法及其局限性.
评估组合策略,包括受体氨酸激酶,SHP2,SOS1抑制剂和BCL-XL降解剂.

主要成果:

克拉斯抑制剂显示有前途,但面临抗性问题.
索托拉西布 (G12C 抑制剂) 与 DT2216 (BCL-XL 降解剂) 的组合协同抑制了 G12C 突变的胰腺癌.
组合疗法增强了亡诱导,克服了诸如衰老之类的抵抗机制.

结论:

针对KRAS的疗法正在发展,G12D突变的新抑制剂正在出现.
组合策略对于克服KRAS突变胰腺癌的治疗耐药性至关重要.
针对KRAS,特别是G12D突变,以及诱导亡的药物,为胰腺癌提供了一个有希望的治疗途径.

关键词:

组合疗法是一种组合疗法.药物耐药性药物耐药性药物耐药性克拉斯 (Kras) 是一个国家.瘤原体信号传递胰腺癌是一种胰腺癌.衰老是一种衰老.有针对性的治疗.

更多相关视频

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...